Biosimilars

thumbnail
Bioprocess Insider
A mAb for all seasons: B-I teams with GoodRx to distribute Humira biosimilarA mAb for all seasons: B-I teams with GoodRx to distribute Humira biosimilar

A deeply discounted biosimilar to treat autoimmune conditions has been approved for US distribution.

byJosh Abbott, Editor, BioProcess Insider
Jul 22, 2024
|
1 Min Read
Streamlining and Accelerating Biosimilar Adoption in the United States logo in a gray background |
Biosimilars
Streamlining and Accelerating Biosimilar Adoption in the United StatesStreamlining and Accelerating Biosimilar Adoption in the United States
byJin Ah Jung
May 17, 2023
Surveying the Biosimilars Regulatory Landscape
Biosimilars
Surveying the Biosimilars Regulatory LandscapeSurveying the Biosimilars Regulatory Landscape
byBrian Gazaille, Tina Morris
Aug 19, 2022
Accelerating Antibody Discovery through Gator<sup>&reg;</sup> BLI Biosensor Technology
Sponsored Content
Accelerating Antibody Discovery through Gator® BLI Biosensor TechnologyAccelerating Antibody Discovery through Gator® BLI Biosensor Technology
byBPI Contributor
Jul 28, 2022
1 Min Read
The Biosimilars Action Plan: Promoting Faster and More Extensive Adoption of Biosimilar Drugs
Biosimilars
The Biosimilars Action Plan: Promoting Faster and More Extensive Adoption of Biosimilar DrugsThe Biosimilars Action Plan: Promoting Faster and More Extensive Adoption of Biosimilar Drugs
byKevin E. Noonan
Dec 8, 2021
Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly
Sponsored Content
Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA ProductBiosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product
byBPI Contributor
Sep 3, 2021
1 Min Read
Biosimilars Pipeline and Market Trends
Biosimilars
Biosimilars Pipeline and Market Trends
Biosimilars Pipeline and Market Trends
Jun 12, 2020
byRonald A. Rader
A Healthy Biosimilars Market Promotes Innovation and Affordability
Economics
A Healthy Biosimilars Market Promotes Innovation and Affordability
A Healthy Biosimilars Market Promotes Innovation and Affordability
May 24, 2020
byWayne Winegarden
Building Orthogonality into Biosimilar Testing
Sponsored Content
Building Orthogonality into Biosimilar Testing
Building Orthogonality into Biosimilar Testing
Apr 13, 2020
byRichard L. Easton
Evaluating Biosimilars: A View from the Small-Molecule World
Biosimilars
Evaluating Biosimilars: A View from the Small-Molecule World
Evaluating Biosimilars: A View from the Small-Molecule World
Feb 7, 2020
byEmil W. Ciurczak
Risk and Lifecycle Management for Biopharma Operations
Sponsored Content
Risk and Lifecycle Management for Biopharma Operations
Risk and Lifecycle Management for Biopharma Operations
Dec 16, 2019
byBPI Contributor
Biosimilarity Assessments: The Totality of Evidence Framework
Sponsored Content
Biosimilarity Assessments: The Totality of Evidence Framework
Biosimilarity Assessments: The Totality of Evidence Framework
Sep 21, 2019
+1
byJose Menezes, Anna C. Loiaand 1 more
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving US Law
Intellectual Property
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving US Law
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving US Law
May 17, 2019
+1
byStacie L. Ropka, Drew A. Hillierand 1 more
Biosimilars: Challenging the Justifications for Clinical Testing
Biosimilars
Biosimilars: Challenging the Justifications for Clinical Testing
Biosimilars: Challenging the Justifications for Clinical Testing
Jan 31, 2019
bySarfaraz Niazi
Innovators and Biosimilar Companies: Experts Predict Intense Conflicts Ahead logo in a gray background | Innovators and Biosimilar Companies: Experts Predict Intense Conflicts Ahead
Regulatory Affairs
Innovators and Biosimilar Companies: Experts Predict Intense Conflicts Ahead
Innovators and Biosimilar Companies: Experts Predict Intense Conflicts Ahead
Jun 20, 2018
byAlison Center
An Approach to Generating Better Biosimilars: Considerations in Controlling Glycosylation Variability in Protein Therapeutics
Process Development
An Approach to Generating Better Biosimilars: Considerations in Controlling Glycosylation Variability in Protein Therapeutics
An Approach to Generating Better Biosimilars: Considerations in Controlling Glycosylation Variability in Protein Therapeutics
Feb 15, 2018
+3
byLori Fortin, Jonathan Furaand 3 more
eBook: Challenges Facing Biosimilar Entries into US Markets
Biosimilars
eBook: Challenges Facing Biosimilar Entries into US Markets
eBook: Challenges Facing Biosimilar Entries into US Markets
Jan 16, 2018
bySarfaraz Niazi
Controlling Glycosylation in Fusion Protein Manufacturing to Generate Potent Biobetters
Biosimilars
Controlling Glycosylation in Fusion Protein Manufacturing to Generate Potent Biobetters
Controlling Glycosylation in Fusion Protein Manufacturing to Generate Potent Biobetters
Sep 19, 2017
byStefan R. Schmidt
Opportunities and Challenges in Biosimilar Development
Biosimilars
Opportunities and Challenges in Biosimilar Development
Opportunities and Challenges in Biosimilar Development
May 18, 2017
+1
bySanjeev K. Gupta, Pankaj S. Chaudhariand 1 more
Accelerating Biosimilar Development Programs using Contract Testing and Manufacturing Organizations
Sponsored Content
Accelerating Biosimilar Development Programs using Contract Testing and Manufacturing Organizations
Accelerating Biosimilar Development Programs using Contract Testing and Manufacturing Organizations
Apr 26, 2017
|
1 Min Read
byBPI Contributor
Contract Test Services from Associates of Cape Cod, Inc.: Specializing in Testing for Endotoxin and Glucan Contamination logo in a gray background | Contract Test Services from Associates of Cape Cod, Inc.: Specializing in Testing for Endotoxin and Glucan Contamination
Sponsored Content
Contract Test Services from Associates of Cape Cod, Inc.: Specializing in Testing for Endotoxin and Glucan Contamination
Contract Test Services from Associates of Cape Cod, Inc.: Specializing in Testing for Endotoxin and Glucan Contamination
Apr 26, 2017
|
1 Min Read
byBPI Contributor
Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin logo in a gray background | Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin
Sponsored Content
Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin
Platform Purification of Six Biosimilar Molecules Using Amsphere A3 – Protein A Resin
Apr 26, 2017
|
1 Min Read
byBPI Contributor
Introduction: Tackling the Technical and Regulatory Challenges of Biosimilar Development
Biosimilars
Introduction: Tackling the Technical and Regulatory Challenges of Biosimilar Development
Introduction: Tackling the Technical and Regulatory Challenges of Biosimilar Development
Apr 18, 2017
byCheryl Scott
Advancements in Characterizing Therapeutic Protein Higher-Order Structure logo in a gray background | Advancements in Characterizing Therapeutic Protein Higher-Order Structure
Laboratory Equipment
Advancements in Characterizing Therapeutic Protein Higher-Order Structure
Advancements in Characterizing Therapeutic Protein Higher-Order Structure
Apr 18, 2017
byMike Bogan, Henry Benner
Biosimilar Markets and Regulation: Which Countries Are Going All In? logo in a gray background | Biosimilar Markets and Regulation: Which Countries Are Going All In?
Biosimilars
Biosimilar Markets and Regulation: Which Countries Are Going All In?
Biosimilar Markets and Regulation: Which Countries Are Going All In?
Apr 12, 2017
byRonald A. Rader
The Clinical Side of Biosimilar Development
Biosimilars
The Clinical Side of Biosimilar Development
The Clinical Side of Biosimilar Development
Apr 12, 2017
byBruno Speder
Evolving Bioassay Strategies for Therapeutic Antibodies: Essential Information for Proving Biosimilarity
Biosimilars
Evolving Bioassay Strategies for Therapeutic Antibodies: Essential Information for Proving Biosimilarity
Evolving Bioassay Strategies for Therapeutic Antibodies: Essential Information for Proving Biosimilarity
Apr 12, 2017
byUlrike Herbrand
Outsourcing Biosimilar Development
Contract Services
Outsourcing Biosimilar Development
Outsourcing Biosimilar Development
Mar 14, 2017
byCassidy Cantin, Kristi Sarno
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2
Biosimilars
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2
Nov 14, 2016
+3
bySimran J. Kaur, Darryl Sampeyand 3 more
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1
Biosimilars
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1
Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1
Oct 14, 2016
+3
bySimran J. Kaur, Darryl Sampeyand 3 more
Outsourcing Trends in Biosimilars Development: A Discussion with Niall Dinwoodie (Charles River Laboratories)
Biosimilars
Outsourcing Trends in Biosimilars Development: A Discussion with Niall Dinwoodie (Charles River Laboratories)
Outsourcing Trends in Biosimilars Development: A Discussion with Niall Dinwoodie (Charles River Laboratories)
Sep 15, 2016
byMaribel Rios
Enhanced Biosimilar Product Characterization: A Case Study Using Raman Spectroscopy Combined with Dynamic Light Scattering
Product Characterization
Enhanced Biosimilar Product Characterization: A Case Study Using Raman Spectroscopy Combined with Dynamic Light Scattering
Enhanced Biosimilar Product Characterization: A Case Study Using Raman Spectroscopy Combined with Dynamic Light Scattering
Jun 15, 2016
+3
byWei Qi, Stacy Kenyonand 3 more
Single-Use Technology Enables Flexible Factories
Single Use
Single-Use Technology Enables Flexible Factories
Single-Use Technology Enables Flexible Factories
Jun 15, 2016
byJennifer Campbell, Sebastien Ribault
Future Manufacturing Strategies for Biosimilars
Biosimilars
Future Manufacturing Strategies for Biosimilars
Future Manufacturing Strategies for Biosimilars
May 17, 2016
byRonald A. Rader, Eric S. Langer
Outsourcing Biosimilars Development
Biosimilars
Outsourcing Biosimilars Development
Outsourcing Biosimilars Development
May 17, 2016
byNiall Dinwoodie

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Advanced CLD with S-CHOice®: Higher Productivity with Transposase Technology and Improved ADCC with S-AfuCHO™
Register Now: Advanced CLD with S-CHOice®: Higher Productivity with Transposase Technology and Improved ADCC with S-AfuCHO™
Insider News
See all
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More

Innovative Technology

Bruker Tornado Spectroscopy
Sponsored Content
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy
Monitoring and Controlling Upstream Bioprocesses with Raman Spectroscopy

Dec 1, 2024

Thermo Fisher White Paper
Sponsored Content
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies
Peptones: A Powerful Tool for Manufacturing Complex Protein Therapies

Nov 21, 2024

Thermo Fisher WP
Sponsored Content
Efficient-Pro Medium and Feed 1 Enable Rapid and Seamless Upstream Process Development and Scale-Up for CHO-K1 Cells
Efficient-Pro Medium and Feed 1 Enable Rapid and Seamless Upstream Process Development and Scale-Up for CHO-K1 Cells

Nov 21, 2024